11:00 AM - 11:15 AM ET
From early access to commercial market: The patient experience
The landmark approval of Revolution Medicine’s pancreatic cancer drug daraxonrasib marked a huge step forward in treatment of the disease. It also opened up a temporary no-mans land: approval meant closing off early access programs for the drug, but commercial pathways to treatment weren’t immediately available. How do patients and doctors navigate these gaps?